Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:02:45.225Z.
Consensus retrieved: 2026-10-06T11:54:42.310Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:02:45.225Z.
Quote observation: 2026-10-06T15:00:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Forward PE Ratio (N/A) = Dated Quote Price ($13.86) / Consensus Forward EPS ($-2.28)
FORWARD PE RATIO
N/A
Generate Biomedicines, Inc.
Market Cap
$1.78B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.78B | N/A |
| Absci Corporation (ABSI)vs › | $1.81B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | 5.63 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 27.78 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.71B | 45.31 |
| Novocure Ltd (NVCR)vs › | $1.83B | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 26.58 |
| Novavax, Inc. (NVAX)vs › | $1.87B | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $13.86, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.28 | $-2.49 – $-2.13 | 4 | n/m |
| 2027-12-31 | $-2.29 | $-2.90 – $-1.63 | 4 | n/m |
| 2028-12-31 | $-1.78 | $-2.06 – $-1.50 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
